Metrological traceability in mass spectrometry-based targeted protein quantitation: A proof-of-principle study for serum apolipoproteins A-I and B100

Journal of Proteomics

Volumn 109, Issue , 2014, Pages 143-161

  Smit, Nico P M ^a   Romijn, Fred P H T M ^a   van den Broek, Irene ^a   Drijfhout, Jan W ^a   Haex, Martin ^b   van der Laarse, Arnoud ^a   van der Burgt, Yuri E M ^a   Cobbaert, Christa M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Agilent Technologies Netherlands BV   (Netherlands)

Author keywords

Apolipoproteins; Biomarker; Cardiovascular disease; Clinical chemistry; Metrological traceability; Multiple reaction monitoring

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STABLE ISOTOPE; PEPTIDE;

AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN TARGETING; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; BLOOD; DYSLIPIDEMIA; PROCEDURES; STANDARDS;

APOLIPOPROTEIN A-I; APOLIPOPROTEIN B-100; DYSLIPIDEMIAS; HUMANS; MASS SPECTROMETRY; PEPTIDES;

EID: 84904338219     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2014.06.015     Document Type: Article

References (46)

1. Langlois M.R., Descamps O.S., van der Laarse A., Weykamp C., Baum H., Pulkki K., et al. Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project Group. Atherosclerosis 2014, 233:83-90.
2. Horvath A.R., Lord S.J., St John A., Sandberg S., Cobbaert C.M., Lorenz S., et al. From biomarkers to medical tests: the changing landscape of test evaluation. Clin Chim Acta 2014, 427:49-57.
3. Reiner Z., Catapano A.L., De Backer G., Graham I., Taskinen M.R., Wiklund O., et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32(14):1769-1818.
4. Fernandez M.L., Webb D. The LDL to HDL cholesterol ratio as a valuable tool to evaluate coronary heart disease risk. J Am Coll Nutr 2008, 27(1):1-5.
5. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18(6):499-502.
6. Agrawal M., Spencer H.J., Faas F.H. Method of LDL cholesterol measurement influences classification of LDL cholesterol treatment goals: clinical research study. J Investig Med 2010, 58(8):945-949.
7. Baruch L., Agarwal S., Gupta B., Haynos A., Johnson S., Kelly-Johnson K., et al. Is directly measured low-density lipoprotein clinically equivalent to calculated low-density lipoprotein?. J Clin Lipidol 2010, 4(4):259-264.
8. Miller W.G., Myers G.L., Sakurabayashi I., Bachman L.M., Caudill S.P., Dziekonski A., et al. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clin Chem 2010, 55(6):977-986.
9. Dominiczak M.H., Caslake M.J. Apolipoproteins: metabolic role and clinical biochemistry applications. Ann Clin Biochem 2011, 48(Pt 6):498-515.
10. Sniderman A.D., Williams K., Contois J.H., Monroe H.M., McQueen M.J., de Graaf J., et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011, 4(3):337-345.
11. Sniderman A., Williams K., Cobbaert C. ApoB versus non-HDL-C: what to do when they disagree. Curr Atheroscler Rep 2009, 11(5):358-363.
12. Di Angelantonio E., Sarwar N., Perry P., Kaptoge S., Ray K.K., Thompson A., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302(18):1993-2000.
13. Jungner I., Marcovina S.M., Walldius G., Holme I., Kolar W., Steiner E. Apolipoprotein B and A-I values in 147576 Swedish males and females, standardized according to the World Health Organization-International Federation of Clinical Chemistry First International Reference Materials. Clin Chem 1998, 44(8 Pt 1):1641-1649.
14. Hoofnagle A.N., Wener M.H. The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J Immunol Methods 2009, 347(1-2):3-11.
15. van den Broek I., Smit N.P., Romijn F.P., van der Laarse A., Deelder A.M., van der Burgt Y.E., et al. Evaluation of inter-specimen trypsin digestion efficiency prior to MRM-based absolute protein quantification with native protein calibrators. J Proteome Res 2013, 12(12):5760-5774.
16. Lehmann S., Hoofnagle A., Hochstrasser D., Brede C., Glueckmann M., Cocho J.A., et al. Quantitative Clinical Chemistry Proteomics (qCCP) using mass spectrometry: general characteristics and application. Clin Chem Lab Med 2013, 51(5):919-935.
17. Barr J.R., Maggio V.L., Patterson D.G., Cooper G.R., Henderson L.O., Turner W.E., et al. Isotope dilution-mass spectrometric quantification of specific proteins: model application with apolipoprotein A-I. Clin Chem 1996, 42(10):1676-1682.
18. Agger S.A., Marney L.C., Hoofnagle A.N. Simultaneous quantification of apolipoprotein A-I and apolipoprotein B by liquid-chromatography-multiple- reaction-monitoring mass spectrometry. Clin Chem 2010, 56(12):1804-1813.
19. Hoofnagle A.N., Becker J.O., Oda M.N., Cavigiolio G., Mayer P., Vaisar T. Multiple-reaction monitoring-mass spectrometric assays can accurately measure the relative protein abundance in complex mixtures. Clin Chem 2012, 58(4):777-781.
20. Kay R.G., Gregory B., Grace P.B., Pleasance S. The application of ultra-performance liquid chromatography/tandem mass spectrometry to the detection and quantitation of apolipoproteins in human serum. Rapid Commun Mass Spectrom 2007, 21(16):2585-2593.
21. Lassman M.E., McLaughlin T.M., Somers E.P., Stefanni A.C., Chen Z., Murphy B.A., et al. A rapid method for cross-species quantitation of apolipoproteins A1, B48 and B100 in plasma by ultra-performance liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2012, 26(2):101-108.
22. Ceglarek U., Dittrich J., Becker S., Baumann F., Kortz L., Thiery J. Quantification of seven apolipoproteins in human plasma by proteoptypic peptides using fast LC-MS/MS. Proteomics Clin Appl 2013, 7(11-12):794-801.
23. Rezeli M., Vegvari A., Fehniger T.E., Laurell T., Marko-Varga G. Moving towards high density clinical signature studies with a human proteome catalogue developing multiplexing mass spectrometry assay panels. J Clin Bioinform 2011, 1(1):7.
24. Anderson L., Hunter C.L. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006, 5(4):573-588.
25. Campbell J., Rezai T., Prakash A., Krastins B., Dayon L., Ward M., et al. Evaluation of absolute peptide quantitation strategies using selected reaction monitoring. Proteomics 2011, 11(6):1148-1152.
26. Kuzyk M.A., Smith D., Yang J., Cross T.J., Jackson A.M., Hardie D.B., et al. Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol Cell Proteomics 2009, 8(8):1860-1877.
27. McKay M.J., Sherman J., Laver M.T., Baker M.S., Clarke S.J., Molloy M.P. The development of multiple reaction monitoring assays for liver-derived plasma proteins. Proteomics Clin Appl 2007, 1(12):1570-1581.
28. Keshishian H., Addona T., Burgess M., Mani D.R., Shi X., Kuhn E., et al. Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics 2009, 8(10):2339-2349.
29. Fraser C.G. Dundee Scotland 2001, 1-132. It was published by the American Association of Clinical Chemistry (AACC Press, Washington, DC, USA 20006-2213).
30. Smit N., van den Broek I., Romijn F.P., Haex M., Deelder A.M., van der Burgt Y., et al. Quality requirements for quantitative clinical chemistry proteomics. Transl Proteomics 2014, 2(1):1-13.
31. Armbruster D., Miller R.R. The Joint Committee for Traceability in Laboratory Medicine (JCTLM): a global approach to promote the standardisation of clinical laboratory test results. Clin Biochem Rev 2007, 28(3):105-113.
32. Carr S.A., Abbatiello S.E., Ackermann B.L., Borchers C., Domon B., Deutsch E.W., et al. Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol Cell Proteomics 2014, [M113.036095 [pii]]. 10.1074/mcp.M113.036095.
33. Marcovina S.M., Albers J.J., Henderson L.O., Hannon W.H. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. Clin Chem 1993, 39(5):773-781.
34. Marcovina S.M., Albers J.J., Kennedy H., Mei J.V., Henderson L.O., Hannon W.H. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material. Clin Chem 1994, 40(4):586-592.
35. Lieske J.C., Bondar O., Miller W.G., Bachmann L.M., Narva A.S., Itoh Y., et al. A reference system for urinary albumin: current status. Clin Chem Lab Med 2013, 51(5):981-989.
36. Vandermarliere E., Mueller M., Martens L. Getting intimate with trypsin, the leading protease in proteomics. Mass Spectrom Rev 2013, 10.1002/mas.21376.
37. Abbatiello S.E., Mani D.R., Schilling B., Maclean B., Zimmerman L.J., Feng X., et al. Design, implementation and multi-site evaluation of a system suitability protocol for the quantitative assessment of instrument performance in LC-MRM-MS. Mol Cell Proteomics 2013, 12(4):2623-2639.
38. Chase D.H., Barr J.R., Duncan M.W., Matern D., Morris M.R., Palmer-Toy D.E., et al. Mass spectrometry in the clinical laboratory: general principles and guidance; approved guideline C50-A. 27[24] 2007, 1-93. Clinical and Laboratory Standards Institute (CLSI), Wayne, P.A.
39. Gallien S., Duriez E., Demeure K., Domon B. Selectivity of LC-MS/MS analysis: implication for proteomics experiments. J Proteomics 2013, 81:148-158.
40. Percy A.J., Chambers A.G., Yang J., Jackson A.M., Domanski D., Burkhart J., et al. Method and platform standardization in MRM-based quantitative plasma proteomics. J Proteomics 2013, 95:66-76.
41. Proc J.L., Kuzyk M.A., Hardie D.B., Yang J., Smith D.S., Jackson A.M., et al. A quantitative study of the effects of chaotropic agents, surfactants, and solvents on the digestion efficiency of human plasma proteins by trypsin. J Proteome Res 2010, 9(10):5422-5437.
42. Rezeli M., Vegvari A., Donnarumma F., Gidlof O., Smith J.G., Erlinge D., et al. Development of an MRM assay panel with application to biobank samples from patients with myocardial infarction. J Proteomics 2013, 87:16-25.
43. Keshishian H., Addona T., Burgess M., Kuhn E., Carr S.A. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics 2007, 6(12):2212-2229.
44. Vesper H.W., Miller W.G., Myers G.L. Reference materials and commutability. Clin Biochem Rev 2007, 28(4):139-147.
45. Addona T.A., Abbatiello S.E., Schilling B., Skates S.J., Mani D.R., Bunk D.M., et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 2009, 27(7):633-641.
46. Prakash A., Rezai T., Krastins B., Sarracino D., Athanas M., Russo P., et al. Platform for establishing interlaboratory reproducibility of selected reaction monitoring-based mass spectrometry peptide assays. J Proteome Res 2010, 9(12):6678-6688.